Skye Bioscience Inc
NASDAQ:SKYE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.44
18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Skye Bioscience Inc
Skye Bioscience Inc
Total Current Liabilities
Skye Bioscience Inc
Total Current Liabilities Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Skye Bioscience Inc
NASDAQ:SKYE
|
Total Current Liabilities
$14.3m
|
CAGR 3-Years
110%
|
CAGR 5-Years
5%
|
CAGR 10-Years
80%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$10.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$21.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.5B
|
CAGR 3-Years
25%
|
CAGR 5-Years
23%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
26%
|
See Also
What is Skye Bioscience Inc's Total Current Liabilities?
Total Current Liabilities
14.3m
USD
Based on the financial report for Jun 30, 2024, Skye Bioscience Inc's Total Current Liabilities amounts to 14.3m USD.
What is Skye Bioscience Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
80%
Over the last year, the Total Current Liabilities growth was 46%. The average annual Total Current Liabilities growth rates for Skye Bioscience Inc have been 110% over the past three years , 5% over the past five years , and 80% over the past ten years .
You don't have any saved screeners yet
